Uncategorized Archives - Page 20 of 249

FridayMay 26, 2023 10:30 am

The Green Label Expo: Las Vegas 2023 Edition

The Green Label Expo 2023 edition will be held at the World Market Center in Las Vegas on the 13th & 14th of September, welcoming thousands of CBD experts, alternative product professionals, counterculture experts, and business owners to discover a vast array of global suppliers in trending sectors such as beauty, health & wellness, pet products, foods, business services, and more. As the need for embracing alternative products surges, the vibrant city of Las Vegas is set to welcome the largest trade show for CBD and alternative product professionals. This two-day event will feature an extensive showcase of innovative products/services,…

FridayMay 26, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023 On the agenda were the election of six director nominees, the ratification of the appointment of the company’s independent registered public accounting firm, and the approval of a one-time repricing of specific issued stock options, among others All items presented received approval, with the highest approval percentage standing at 97.6% and the lowest at 63.1% The meeting presented an opportunity for Lexaria to evaluate areas of expertise that would provide additional benefits to the company and its shareholders while also adding diversity to its board Lexaria Bioscience (NASDAQ:…

TuesdayMay 23, 2023 11:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology Lexaria is currently seeking IND status from the FDA for use of DehydraTECH-processed CBD with hypertension and expects to begin dosing a new human clinical trial in October 2023 Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

MondayMay 22, 2023 11:15 am

Lift Toronto 2023 Conference & Expo: Lifting the Rapidly Expanding Cannabis Industry & Community

Cannabis industry leaders, entrepreneurs, policymakers, service providers and consumers are all invited to attend the Lift Toronto 2023 Conference & Expo to be held at Metro Toronto Convention Centre from June 1-3, 2023. The advocacy-oriented, strategy-focused Lift Cannabis Business Conference (“LCBC”) on June 1st kicks off the three-day event and is dedicated to discussing best practices in evolving cannabis industry topics, brushing up on policy matters, and connecting with industry leaders. The Lift Cannabis Business Conference is an ideal opportunity for those who are serious about thriving in the global cannabis industry; it is the premiere gathering of subject matter…

MondayMay 22, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine and delivered up to 6-fold higher levels of nicotine into blood plasma than concentration-matched controls If the findings from the human study replicate a similarly improved performance, Lexaria believes this could facilitate a more…

FridayMay 19, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1…

TuesdayMay 16, 2023 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Promises to Energize, Inspire, Educate, and Motivate Audiences from Across the Cannabis Ecosystem

In October 2018, Canada became the first developed country to legalize recreational cannabis for adult use (https://cnw.fm/CnFvC). Aimed at curbing the illicit trade of the drug and launching a new source of economic growth, this move is playing a significant role in the economy. For instance, Deloitte’s study, which considered the direct, indirect, and induced economic activities, estimated that the industry had contributed US$43.5 billion to Canada’s economy between legalization and 2021 (https://cnw.fm/2CPiB). And as the country counts down to the fifth anniversary this October, the figure is expected to be higher, making the upcoming Lift Toronto 2023 Cannabis Conference…

TuesdayMay 16, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of…

TuesdayMay 16, 2023 4:20 am

420 with CNW — U.S. Border Patrol Agents Cautioned Against Using CBD Products

The U.S. Customs and Border Protection agency is warning its workers and their family members to say no to CBD. CBD (cannabidiol) is one of the two primary compounds found in marijuana. However, unlike THC, which induces a high when ingested, CBD does not. In a recently published advisory, the agency highlighted some issues associated with this compound, highlighting that CBD products were still unregulated and could contain THC that can be detectable using a drug test. It should be noted that the agency isn't forbidding its workers from using CBD products derived from hemp, because the substance was legalized…

FridayMay 12, 2023 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Connects Brands, Investors, Growers & Consumers from Across the Cannabis Industry

Cannabis industry growers, processors, manufacturers, brands, budtenders, retailers, educators, advocates, regulators, consumers, investors, and more, are invited to attend the Lift Toronto 2023 Cannabis Conference & Expo to be held June 1-3, 2023, at the Metro Toronto Convention Centre. The three-day event will begin on Thursday, June 1, with the Lift Cannabis Business Conference (“LCBC”), an all-business strategy forum focused on generating meaningful change and sustainable growth within the Canadian cannabis industry. The conference will focus on the drivers of forward momentum, overcoming systemic challenges, and advancing innovative business and regulatory solutions. The LCBC sessions will include highlights such as…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized